Clustered Circulating Tumor Cells as a Predictor of Adjuvant-chemotherapy Efficacy in Lung Cancer.

Autor:	Sawabata N; Department of General Thoracic Surgery, Nara Medical University Hospital, Kashihara City, Japan; Department of General Thoracic Surgery, JCHO Hoshigaoka Medical Center, Hirakata, Japan; Department of General Thoracic Surgery, Kawanishi City Medical Center, Kawanishi City, Japan. Electronic address: nsawabata@hotmail.com., Hamaji M; Department of General Thoracic Surgery, Nara Medical University Hospital, Kashihara City, Japan., Yoshikawa D; Department of General Thoracic Surgery, Nara Medical University Hospital, Kashihara City, Japan., Miyata R; Department of General Thoracic Surgery, Nara Medical University Hospital, Kashihara City, Japan., Kawaguchi T; Department of General Thoracic Surgery, Nara Medical University Hospital, Kashihara City, Japan.
Jazyk:	angličtina
Zdroj:	The Annals of thoracic surgery [Ann Thorac Surg] 2024 Nov; Vol. 118 (5), pp. 1136-1143. Date of Electronic Publication: 2024 May 23.
DOI:	10.1016/j.athoracsur.2024.05.005
Abstrakt:	Background: Surrogate markers of minimal residual disease primarily include cell-free tumor DNA and circulating tumor cells. Cell-free tumor DNA might aid precise decision-making regarding who should receive adjuvant chemotherapy. However, there are no relevant reports on circulating tumor cells. Therefore, we aimed to verify whether perioperative clustered circulating tumour cells identification is a predictor of therapeutic efficacy in non-small cell lung cancer adjuvant chemotherapy. Methods: Circulating tumor cells were diagnosed under light microscopy using a size selection method in 128 patients with clinical stage I/II non-small cell lung cancer around surgery. The main endpoint was recurrence-free survival, and the effect of adjuvant chemotherapy was verified in both groups based on perioperative clustered circulating tumor cell identification. Results: In total, 49 and 79 patients were included in the clustered circulating tumor cell-positive and clustered circulating tumor cell-negative patient groups, respectively. In the clustered circulating tumor cell-positive patient group, adjuvant chemotherapy was performed in 18 patients (2-year recurrence-free survival rate, 71.8%). However, the 2-year recurrence-free survival rate was 36.3% in 31 patients who did not receive adjuvant chemotherapy (P < .01). In the clustered circulating tumor cell-negative patient group, adjuvant chemotherapy was provided in 11 patients (2-year recurrence-free survival rate, 90.9%). However, 68 patients did not receive adjuvant chemotherapy (2-year recurrence-free survival rate, 94.9%) (not significant). Conclusions: In surgical cases of clinical stage I/II non-small cell lung cancer, patients with perioperative clustered circulating tumor cells had a poor prognosis, but adjuvant chemotherapy improved their prognosis. Competing Interests: Disclosures The authors have no conflicts of interest to disclose. (Copyright © 2024 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu